卡地纳健康公司近日发布业绩展望,其生物制药解决方案部门在2026财年有望实现超过30%的营收增长。这一积极预期凸显了该公司在医药分销领域的战略布局正收获显著成效。
随着全球生物制药市场持续扩张,卡地纳健康通过优化供应链管理和拓展专业服务能力,成功抓住了行业增长机遇。公司管理层表示,这一增长动力主要来源于与生物技术企业合作的深化及特药分销网络的扩展。
卡地纳健康公司近日发布业绩展望,其生物制药解决方案部门在2026财年有望实现超过30%的营收增长。这一积极预期凸显了该公司在医药分销领域的战略布局正收获显著成效。
随着全球生物制药市场持续扩张,卡地纳健康通过优化供应链管理和拓展专业服务能力,成功抓住了行业增长机遇。公司管理层表示,这一增长动力主要来源于与生物技术企业合作的深化及特药分销网络的扩展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.